skip navigation links
National Center for Complementary and
Alternative Medicine (NCCAM)
National Insitutes of Health
Text size  A A Contact Us Site Map
       
Home  Health Information  Research  Training  Clinical Trials  News and Events  About NCCAM

Back to: Health Information

FDA Warning on Androstenedione (Andro)

March 11, 2004
Consumer Advisory

The U.S. Food and Drug Administration (FDA) has announced a crackdown on products containing androstenedione, commonly known as "andro." The products are marketed over the counter as dietary supplements that enhance athletic performance. In the body, androstenedione is converted into testosterone and estrogen.

While ads claim that andro-containing supplements promote increased muscle mass, research has not shown this to be the case. In addition, studies have shown side effects and potential long-term risks; androstenedione poses the same kinds of health risks as anabolic steroids. Given the lack of proven benefits and the risks, the FDA is requesting companies to stop distributing dietary supplements containing androstenedione. The FDA is also encouraging Congress to consider legislation to classify these products as a controlled substance.

Potential Long-Term Risks

  • For men--shrinkage of testicles, growth of breast tissue, impotence
  • For women--male pattern baldness, increased facial hair, increased risk for breast cancer and endometrial cancer, blood clots
  • For youth--acne, early start of puberty, stunted growth

Advice to Consumers

Consumers should understand that there are risks for serious side effects. Do not take supplements with andro.

More Information


Top

Mail icon Send this link to a friend
PDF logo Printer-friendly version
Dictionary icon Medical dictionary

 
 NIH logo    H H S logo - link to U. S. Department of Health and Human Services    FirstGov logo